Twitter | Search | |
Search Refresh
Davide Capodanno 10h
Bingo! One of the fellows is preparing for a "critical thinking" examination and just wrote me to ask why in the safety analysis is carried out with 210 less patients in the prasugrel arm. I like when they look at the fine prints.😈
Reply Retweet Like
Bartosz Hudzik MD PhD FESC Sep 16
Reply Retweet Like
Dr. Rohan P. Parikh Sep 2
trial Intracoronary Stenting and Antithrombotic Regimen 5
Reply Retweet Like
Harriette Van Spall, MD MPH Sep 5
⁩ papers for major available via this handy link! & more!! ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁦⁩ ⁦
Reply Retweet Like
Tania Ahuja Sep 26
just when you finally digested you get this 💎 to 😬 monotx after 3 months of following among high-risk patients associated with ⬇️ bleeding & no ⬆️ risk of death, MI, or stroke ⤵️
Reply Retweet Like
StanfordCVFellowship Sep 24
A lot of excitement in the room to discuss ticagrelor vs prasugrel at tonight's journal club!
Reply Retweet Like
Boback Ziaeian 🤦🏻‍♂️ Sep 1
Reply Retweet Like
Nasser Lakkis MD Sep 17
Prasugrel VS Ticagrelor in - Will the results of Trial change your practice? Poll below. Visual abstract
Reply Retweet Like
Harriette Van Spall, MD MPH Sep 5
will change my practice. Barring C/I, will: 1) refer pts w/ for staged PCI ( revasc) after culprit vessel PCI either in hospital or following d/c 2) initiate (vs ticagrelor) in pts w/ or receiving PCI ()👇🏽
Reply Retweet Like
Rohan Khera Sep 1
Replying to @rohan_khera
Woah. Another practice changer. Who would have imagined prasugrel would be substantially superior to ticagrelor in the post ACS setting? Certainly not the current US practice
Reply Retweet Like
Bartosz Hudzik MD PhD FESC Sep 16
Reply Retweet Like
Cardioinfo Sep 20
The late breaking results of the trial have been presented at and published in the . Our interview with principal investigator Stefanie Schüpke:
Reply Retweet Like
José Miguel Torres Viera Sep 1
✳️ ,sorpresa!!🚩Revisión de la práctica ! Prasugrel vs. Ticagrelor , PCI /ACS ▶️The primary outcome of death, myocardial infarction, or stroke at 1 year occurred in 9.3% of the ticagrelor group compared with 6.9% of the prasugrel group (p = 0.006).
Reply Retweet Like
Radcliffe Cardiology Sep 14
Did you catch our first WRAP-UP video with Dr Nicolas Van Mieghem? 🙌 Full video 👉 Did we miss a trial? Did your trial make the cut?
Reply Retweet Like
Thibaut Pommier Sep 3
Professor Gilles Montalescot commenting on the results of study.
Reply Retweet Like
Tania Ahuja Sep 2
⬇️ more than without ⬆️ 🤔 1️⃣ hx of excluded 2️⃣ prasugrel in AFTER coronary angiography/before 3️⃣ dose ⬇️ for ≥75 years or weight <60 kg 4️⃣ median age 65 and majority male 🤷🏻‍♀️ sooo, now what❓⤵️
Reply Retweet Like
Harriette Van Spall, MD MPH Sep 5
Reply Retweet Like
Radcliffe Cardiology Sep 3
Looking forward to filming another video with and later today, on the key and studies presented at this week!
Reply Retweet Like
Harvey Badwal Sep 2
What a year for practice changing science , and the big shocker
Reply Retweet Like
Xacobe Flores Rios Sep 1
At the cath lab waiting for STEMI: ❓Which P2Y12 inhibitor should I choose? ❓Should I apply the results to this patient?
Reply Retweet Like